Comments
Loading...
Stime degli utili, EPS e fatturato
Alnylam Pharmaceuticals segnala gli utili su base trimestrale. Questi report sugli utili trimestrali offrono agli investitori uno sguardo ai risultati finanziari di un'azienda per un periodo di 3 mesi. I report sugli utili includono quasi sempre i risultati EPS e i ricavi.
Data degli utili
ott 30
Stima EPS
$1.120
Stima dei ricavi trimestrali
$961.74M
Ricavi annuali
(a partire da giu 30)
(a partire da giu 30)
$2.46B
Analizza lo storico degli utili di Alnylam Pharmaceuticals utilizzando ordinamenti e filtri avanzati.
Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
ALNY | Alnylam Pharmaceuticals | -$0.50 | $1.12 | — | — | $500.92M | $961.74M | — | — | 10/30/2025 | |
ALNY | Alnylam Pharmaceuticals | $0.58 | -$0.16 | $0.32 | 300.00% | $659.83M | $660.99M | $773.69M | 17.05% | 07/31/2025 | |
ALNY | Alnylam Pharmaceuticals | -$0.16 | -$1.03 | -$0.01 | 99.03% | $494.33M | $585.82M | $594.19M | 1.43% | 05/01/2025 | |
ALNY | Alnylam Pharmaceuticals | -$0.77 | -$0.14 | $0.06 | 142.86% | $439.72M | $580.62M | $593.17M | 2.16% | 02/13/2025 | |
ALNY | Alnylam Pharmaceuticals | $1.74 | -$0.93 | -$0.50 | 46.24% | $750.53M | $533.10M | $500.92M | -6.04% | 10/31/2024 | |
ALNY | Alnylam Pharmaceuticals | -$1.62 | -$1.08 | $0.56 | 151.85% | $318.75M | $444.11M | $659.83M | 48.57% | 08/01/2024 | |
ALNY | Alnylam Pharmaceuticals | -$1.06 | -$1.18 | -$0.16 | 86.44% | $319.29M | $427.33M | $494.33M | 15.68% | 05/02/2024 | |
ALNY | Alnylam Pharmaceuticals | -$1.39 | -$1.33 | -$0.77 | 42.11% | $335.04M | $442.90M | $439.72M | -0.72% | 02/15/2024 | |
ALNY | Alnylam Pharmaceuticals | -$1.58 | -$1.36 | $1.74 | 227.94% | $264.31M | $401.03M | $750.53M | 87.15% | 11/02/2023 | |
ALNY | Alnylam Pharmaceuticals | -$2.03 | -$1.72 | -$1.62 | 5.81% | $224.82M | $331.73M | $318.75M | -3.91% | 08/03/2023 | |
ALNY | Alnylam Pharmaceuticals | -$1.49 | -$1.76 | -$1.06 | 39.77% | $213.26M | $312.26M | $319.29M | 2.25% | 05/04/2023 | |
ALNY | Alnylam Pharmaceuticals | -$1.74 | -$1.90 | -$1.39 | 26.84% | $258.54M | $313.13M | $335.04M | 7.00% | 02/23/2023 | |
ALNY | Alnylam Pharmaceuticals | -$1.59 | -$1.78 | -$1.58 | 11.24% | $187.63M | $293.03M | $264.31M | -9.80% | 10/27/2022 | |
ALNY | Alnylam Pharmaceuticals | -$1.30 | -$1.62 | -$2.03 | -25.31% | $220.55M | $255.88M | $224.82M | -12.14% | 07/28/2022 | |
ALNY | Alnylam Pharmaceuticals | -$1.64 | -$1.84 | -$1.49 | 19.02% | $135.77M | $243.02M | $213.26M | -12.25% | 04/28/2022 | |
ALNY | Alnylam Pharmaceuticals | -$1.60 | -$1.54 | -$1.69 | -9.74% | $163.56M | $233.62M | $258.54M | 10.66% | 02/10/2022 | |
ALNY | Alnylam Pharmaceuticals | -$1.58 | -$1.57 | -$1.51 | 3.82% | $125.85M | $218.69M | $187.63M | -14.20% | 10/28/2021 | |
ALNY | Alnylam Pharmaceuticals | -$1.67 | -$1.60 | -$1.30 | 18.75% | $103.96M | $193.18M | $220.55M | 14.17% | 08/03/2021 | |
ALNY | Alnylam Pharmaceuticals | -$1.52 | -$1.75 | -$1.64 | 6.29% | $99.48M | $168.74M | $177.57M | 5.23% | 04/29/2021 | |
ALNY | Alnylam Pharmaceuticals | -$1.98 | -$1.76 | -$1.60 | 9.09% | $71.68M | $146.07M | $163.56M | 11.98% | 02/11/2021 | |
ALNY | Alnylam Pharmaceuticals | -$1.50 | -$1.66 | -$1.58 | 4.82% | $70.06M | $120.75M | $125.85M | 4.23% | 11/05/2020 |
Alnylam Pharmaceuticals (ALNY) Guadagno per azione
Importo a sorpresa sugli utili trimestrali
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q2 | 2025-07-31 | $0.32 | $-0.16 | 300.0 % |
| Q1 | 2025-05-01 | $-0.01 | $-1.03 | 99.0 % |
| Q4 | 2025-02-13 | $0.06 | $-0.14 | 142.9 % |
| Q3 | 2024-10-31 | $-0.50 | $-0.93 | 46.2 % |
Alnylam Pharmaceuticals (ALNY) Entrate
Importo sorpresa sulle entrate trimestrali
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q2 | 2025-07-31 | $773.69M | $660.99M | 17.1 % |
| Q1 | 2025-05-01 | $594.19M | $585.82M | 1.43 % |
| Q4 | 2025-02-13 | $593.17M | $580.62M | 2.16 % |
| Q3 | 2024-10-31 | $500.92M | $533.10M | -6.04 % |
FAQ
Quando Alnylam Pharmaceuticals (NASDAQ:ALNY) riporterà gli utili?
Si prevede che Alnylam Pharmaceuticals (ALNY) fornisca risultati il ottobre 30, 2025. Gli ultimi risultati sono stati pubblicati il luglio 31, 2025 per il Q2.
Quali sono stati gli ultimi utili per azione (EPS) di Alnylam Pharmaceuticals (NASDAQ:ALNY)?
L'EPS effettivo era $0.32, che superato la stima di $-0.16.
Quali sono state le entrate di Alnylam Pharmaceuticals (NASDAQ:ALNY)?
Le entrate effettive sono state $773.7M, che superato la stima di $661M.
Sfoglia stime sugli utili, EPS e ricavi su tutte le azioni.